203 related articles for article (PubMed ID: 31589480)
41. β-catenin ablation exacerbates polycystic kidney disease progression.
Conduit SE; Hakim S; Feeney SJ; Ooms LM; Dyson JM; Abud HE; Mitchell CA
Hum Mol Genet; 2019 Jan; 28(2):230-244. PubMed ID: 30265301
[TBL] [Abstract][Full Text] [Related]
42. Inhibition of histone deacetylase 6 activity reduces cyst growth in polycystic kidney disease.
Cebotaru L; Liu Q; Yanda MK; Boinot C; Outeda P; Huso DL; Watnick T; Guggino WB; Cebotaru V
Kidney Int; 2016 Jul; 90(1):90-9. PubMed ID: 27165822
[TBL] [Abstract][Full Text] [Related]
43. Pkd1 regulates immortalized proliferation of renal tubular epithelial cells through p53 induction and JNK activation.
Nishio S; Hatano M; Nagata M; Horie S; Koike T; Tokuhisa T; Mochizuki T
J Clin Invest; 2005 Apr; 115(4):910-8. PubMed ID: 15761494
[TBL] [Abstract][Full Text] [Related]
44. Glucose promotes secretion-dependent renal cyst growth.
Kraus A; Schley G; Kunzelmann K; Schreiber R; Peters DJ; Stadler R; Eckardt KU; Buchholz B
J Mol Med (Berl); 2016 Jan; 94(1):107-17. PubMed ID: 26334260
[TBL] [Abstract][Full Text] [Related]
45. Cystic gene dosage influences kidney lesions after nephron reduction.
Le Corre S; Viau A; Burtin M; El-Karoui K; Cnops Y; Terryn S; Debaix H; Bérissi S; Gubler MC; Devuyst O; Terzi F
Nephron; 2015; 129(1):42-51. PubMed ID: 25531116
[TBL] [Abstract][Full Text] [Related]
46. Therapeutic advances in the treatment of polycystic kidney disease.
Riella C; Czarnecki PG; Steinman TI
Nephron Clin Pract; 2014; 128(3-4):297-302. PubMed ID: 25573484
[TBL] [Abstract][Full Text] [Related]
47. The regulatory 1α subunit of protein kinase A modulates renal cystogenesis.
Ye H; Wang X; Constans MM; Sussman CR; Chebib FT; Irazabal MV; Young WF; Harris PC; Kirschner LS; Torres VE
Am J Physiol Renal Physiol; 2017 Sep; 313(3):F677-F686. PubMed ID: 28615245
[TBL] [Abstract][Full Text] [Related]
48. Glucose absorption drives cystogenesis in a human organoid-on-chip model of polycystic kidney disease.
Li SR; Gulieva RE; Helms L; Cruz NM; Vincent T; Fu H; Himmelfarb J; Freedman BS
Nat Commun; 2022 Dec; 13(1):7918. PubMed ID: 36564419
[TBL] [Abstract][Full Text] [Related]
49. Overexpression of PKD1 causes polycystic kidney disease.
Thivierge C; Kurbegovic A; Couillard M; Guillaume R; Coté O; Trudel M
Mol Cell Biol; 2006 Feb; 26(4):1538-48. PubMed ID: 16449663
[TBL] [Abstract][Full Text] [Related]
50. Pax2 gene dosage influences cystogenesis in autosomal dominant polycystic kidney disease.
Stayner C; Iglesias DM; Goodyer PR; Ellis L; Germino G; Zhou J; Eccles MR
Hum Mol Genet; 2006 Dec; 15(24):3520-8. PubMed ID: 17082250
[TBL] [Abstract][Full Text] [Related]
51. Ganoderic acid A is the effective ingredient of Ganoderma triterpenes in retarding renal cyst development in polycystic kidney disease.
Meng J; Sai-Zhen Wang ; He JZ; Zhu S; Huang BY; Wang SY; Li M; Zhou H; Lin SQ; Yang BX
Acta Pharmacol Sin; 2020 Jun; 41(6):782-790. PubMed ID: 31911637
[TBL] [Abstract][Full Text] [Related]
52. Defining a link with autosomal-dominant polycystic kidney disease in mice with congenitally low expression of Pkd1.
Jiang ST; Chiou YY; Wang E; Lin HK; Lin YT; Chi YC; Wang CK; Tang MJ; Li H
Am J Pathol; 2006 Jan; 168(1):205-20. PubMed ID: 16400024
[TBL] [Abstract][Full Text] [Related]
53. Resveratrol delays polycystic kidney disease progression through attenuation of nuclear factor κB-induced inflammation.
Wu M; Gu J; Mei S; Xu D; Jing Y; Yao Q; Chen M; Yang M; Chen S; Yang B; Qi N; Hu H; Wüthrich RP; Mei C
Nephrol Dial Transplant; 2016 Nov; 31(11):1826-1834. PubMed ID: 27190325
[TBL] [Abstract][Full Text] [Related]
54. MicroRNAs regulate renal tubule maturation through modulation of Pkd1.
Patel V; Hajarnis S; Williams D; Hunter R; Huynh D; Igarashi P
J Am Soc Nephrol; 2012 Dec; 23(12):1941-8. PubMed ID: 23138483
[TBL] [Abstract][Full Text] [Related]
55. Polycystin-1 and Gα12 regulate the cleavage of E-cadherin in kidney epithelial cells.
Xu JX; Lu TS; Li S; Wu Y; Ding L; Denker BM; Bonventre JV; Kong T
Physiol Genomics; 2015 Feb; 47(2):24-32. PubMed ID: 25492927
[TBL] [Abstract][Full Text] [Related]
56. Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways.
Takakura A; Nelson EA; Haque N; Humphreys BD; Zandi-Nejad K; Frank DA; Zhou J
Hum Mol Genet; 2011 Nov; 20(21):4143-54. PubMed ID: 21821671
[TBL] [Abstract][Full Text] [Related]
57. Triptolide delays disease progression in an adult rat model of polycystic kidney disease through the JAK2-STAT3 pathway.
Jing Y; Wu M; Zhang D; Chen D; Yang M; Mei S; He L; Gu J; Qi N; Fu L; Li L; Mei C
Am J Physiol Renal Physiol; 2018 Sep; 315(3):F479-F486. PubMed ID: 29513074
[TBL] [Abstract][Full Text] [Related]
58. Inhibition of Hedgehog signaling suppresses proliferation and microcyst formation of human Autosomal Dominant Polycystic Kidney Disease cells.
Silva LM; Jacobs DT; Allard BA; Fields TA; Sharma M; Wallace DP; Tran PV
Sci Rep; 2018 Mar; 8(1):4985. PubMed ID: 29563577
[TBL] [Abstract][Full Text] [Related]
59. Glycogen synthase kinase-3β promotes cyst expansion in polycystic kidney disease.
Tao S; Kakade VR; Woodgett JR; Pandey P; Suderman ED; Rajagopal M; Rao R
Kidney Int; 2015 Jun; 87(6):1164-75. PubMed ID: 25629553
[TBL] [Abstract][Full Text] [Related]
60. Ciclopirox olamine induces ferritinophagy and reduces cyst burden in polycystic kidney disease.
Radadiya PS; Thornton MM; Puri RV; Yerrathota S; Dinh-Phan J; Magenheimer B; Subramaniam D; Tran PV; Zhu H; Bolisetty S; Calvet JP; Wallace DP; Sharma M
JCI Insight; 2021 Mar; 6(8):. PubMed ID: 33784251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
